Show
Sort by
-
Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies
-
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies
-
- Conference Paper
- C3
- open access
Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® improves outcomes versus mono-components in COPD in two 1-year studies
-
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies